CN103930129A - 用于促进凝血的化合物 - Google Patents

用于促进凝血的化合物 Download PDF

Info

Publication number
CN103930129A
CN103930129A CN201280052327.2A CN201280052327A CN103930129A CN 103930129 A CN103930129 A CN 103930129A CN 201280052327 A CN201280052327 A CN 201280052327A CN 103930129 A CN103930129 A CN 103930129A
Authority
CN
China
Prior art keywords
inhibitor
thrombin
antibody
rsl
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280052327.2A
Other languages
English (en)
Chinese (zh)
Inventor
C·E·哈克
C·伊尔迪兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UMC Utrecht Holding BV
Original Assignee
UMC Utrecht Holding BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UMC Utrecht Holding BV filed Critical UMC Utrecht Holding BV
Publication of CN103930129A publication Critical patent/CN103930129A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
CN201280052327.2A 2011-08-25 2012-08-24 用于促进凝血的化合物 Pending CN103930129A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161527140P 2011-08-25 2011-08-25
US61/527,140 2011-08-25
PCT/NL2012/050581 WO2013028070A2 (en) 2011-08-25 2012-08-24 Compounds for use in boosting coagulation

Publications (1)

Publication Number Publication Date
CN103930129A true CN103930129A (zh) 2014-07-16

Family

ID=46845975

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280052327.2A Pending CN103930129A (zh) 2011-08-25 2012-08-24 用于促进凝血的化合物

Country Status (14)

Country Link
US (1) US20140356377A1 (https=)
EP (1) EP2747776B1 (https=)
JP (2) JP6198277B2 (https=)
CN (1) CN103930129A (https=)
AU (1) AU2012299524B2 (https=)
BR (1) BR112014004297B1 (https=)
CA (1) CA2846494C (https=)
CY (1) CY1120688T1 (https=)
DK (1) DK2747776T3 (https=)
ES (1) ES2689776T3 (https=)
HU (1) HUE039590T2 (https=)
PL (1) PL2747776T3 (https=)
PT (1) PT2747776T (https=)
WO (1) WO2013028070A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110753704A (zh) * 2017-06-22 2020-02-04 科马布有限公司 因子ix和因子x的双特异性抗体
US11976135B2 (en) 2018-12-21 2024-05-07 Kymab Limited FIXaxFX bispecific antibody with common light chain

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201506886TA (en) 2013-03-14 2015-09-29 Bayer Healthcare Llc Monoclonal antibodies against antithrombin beta complexed with heparin
EP3212794B1 (en) 2014-10-30 2021-04-07 Genzyme Corporation Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
FI3386518T3 (fi) 2015-12-07 2025-09-25 Genzyme Corp Menetelmiä ja koostumuksia serpinc1:een liittyvän häiriön hoitamiseksi
WO2017158176A1 (en) * 2016-03-18 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-antithrombin single-domain antibodies and polypeptides comprising thereof
JP6883899B1 (ja) * 2020-12-07 2021-06-09 株式会社血栓トランスレーショナルリサーチラボ 血液凝固検査試薬、および血液凝固検査方法
PL440675A1 (pl) * 2022-03-17 2023-09-18 Politechnika Wrocławska Związki do równoległego wykrywania i hamowania proteaz szlaku krzepnięcia - APC, trombiny, czynnika Xa i czynnika XIa w ludzkim osoczu

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009013251A1 (en) * 2007-07-20 2009-01-29 Universite Paris-Sud Xi Use of mutated antithrombins for treating or preventing coagulation disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US748913A (en) * 1904-01-05 Fo model
DE102011081871A1 (de) * 2011-08-31 2013-02-28 Henkel Ag & Co. Kgaa Oxazolidine zur Fehlgeruchsbekämpfung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009013251A1 (en) * 2007-07-20 2009-01-29 Universite Paris-Sud Xi Use of mutated antithrombins for treating or preventing coagulation disorders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
INGEMAR BJORK等: "Conversion of Antithrombin from an Inhibitor of Thrombin to a Substrate with Reduced Heparin Affinity and Enhanced Conformational Stability by Binding of a Tetradecapeptide Corresponding to the P1 to P14 Region of the Putative Reactive Bond Loop of the Inh", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 *
J. ALAIN KUMMER等: "Production, characterization, and use of serpin antibodies", 《METHODS》, vol. 32, 31 December 2004 (2004-12-31), pages 141 - 149, XP004481665, DOI: 10.1016/S1046-2023(03)00205-6 *
L MUSZBEK等: "Antithrombin deficiency and its laboratory diagnosis", 《CL1N1CAL CHEM1STRY AND LABORATORY》, vol. 48, 31 December 2010 (2010-12-31), pages 67 - 78 *
SARAH KNOLLER 等: "Monoclonal antibodies against antithrombin I11 Identification of their epitopes and effects on antithrombin I11 activities", 《EUR.J.BIOCHEM》 *
胡理明 等: "血友病患者抗凝物质及纤溶抑制物质的改变及其在血友病出血机制中的意义", 《血栓与止血学》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110753704A (zh) * 2017-06-22 2020-02-04 科马布有限公司 因子ix和因子x的双特异性抗体
US11919969B2 (en) 2017-06-22 2024-03-05 Kymab Limited Bispecific antibodies for factor IX and factor X
CN110753704B (zh) * 2017-06-22 2024-07-16 科马布有限公司 因子ix和因子x的双特异性抗体
US11976135B2 (en) 2018-12-21 2024-05-07 Kymab Limited FIXaxFX bispecific antibody with common light chain

Also Published As

Publication number Publication date
PL2747776T3 (pl) 2019-03-29
PT2747776T (pt) 2018-10-31
DK2747776T3 (en) 2018-09-17
HUE039590T2 (hu) 2019-01-28
JP6198277B2 (ja) 2017-09-20
AU2012299524B2 (en) 2017-03-23
CA2846494C (en) 2020-10-20
WO2013028070A3 (en) 2013-04-18
EP2747776A2 (en) 2014-07-02
CA2846494A1 (en) 2013-02-28
CY1120688T1 (el) 2019-12-11
WO2013028070A2 (en) 2013-02-28
ES2689776T3 (es) 2018-11-15
JP2014529606A (ja) 2014-11-13
US20140356377A1 (en) 2014-12-04
JP2017186340A (ja) 2017-10-12
BR112014004297B1 (pt) 2021-12-14
EP2747776B1 (en) 2018-07-11
BR112014004297A2 (pt) 2017-03-28
AU2012299524A1 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
CN103930129A (zh) 用于促进凝血的化合物
CA2623142C (en) Methods for a global assay of coagulation and fibrinolysis
JP2020097606A (ja) ｐＫａｌ関連疾病の評価、アッセイおよび治療
US12421298B2 (en) Compositions and methods for evaluating anticoagulant therapeutic efficacy
KR20160026905A (ko) 인자 ｘｉｉ 억제제 및 ｃ1-억제제를 이용한 병용 치료요법
Whelihan et al. Coagulation procofactor activation by factor XIa
JP7689518B2 (ja) グリコカリックス破壊の多因子オントロジーによる疾患をターゲティングしたバイオマーカーパネル
ES2119165T5 (es) Nueva actividad de cofactor anticoagulante.
Lollar Pathogenic antibodies to coagulation factors. Part II. Fibrinogen, prothrombin, thrombin, factor V, factor XI, factor XII, factor XIII, the protein C system and von Willebrand factor
JP2022513332A (ja) プロテインｓレベルの決定方法
JP7635223B2 (ja) 好中球細胞外トラップに関連する線維素溶解不全の診断方法
JPWO2021062298A5 (https=)
McAiney Characterization of the I4399M Variant of Apolipoprotein (a): Implications for Altered Prothrombotic Properties of Lipoprotein (a)
Björkqvist Mechanism and Therapy of Hereditary Angioedema Type III and Role of the Contact System in Inflammatory Diseases
Geng A mechanism for exosite-mediated factor IX activation by factor XIa
Dielis The hypercoagulable state in patients: determining (hyper) coagulability and the role of thrombin generation
AU2012200836A1 (en) Methods for a global assay of coagulation and fibrinolysis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140716